Ensysce Biosciences, Inc. (ENSC): Nasdaq/NYSE listing notice — Ensysce Biosciences receives Nasdaq delisting notice for non-compliance with $2.5M equity requirement

Ensysce Biosciences, Inc.

Notified on Nov 13, 2023 of non-compliance with Nasdaq Rule 5550(b)(1) due to stockholders' equity below $2.5M as of Sept 30, 2023.
Company plans to timely request a hearing before Nasdaq Hearings Panel, staying delisting pending hearing conclusion.
No assurance the Panel will grant continued listing or that compliance can be evidenced within any extension period.
Company intends to actively explore options to regain compliance with Nasdaq listing requirements.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 13, 2023, Ensysce Biosciences, Inc. (the “Company”) received notice from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of September 30, 2023, the Company was subject to delisting unless it timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the conclusion of

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.